Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced a global ...
The New England Journal of Medicine

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

Sunvozertinib received accelerated approval for use in later lines of therapy for patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...
AHA/ASA Journals

Alternative Splicing of TPM1 Mediated by SRPK3 Drives Cardiac Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, a ...
News-Medical.Net

Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for ...
PharmExec

Ascidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editors

RNA exon editing enables replacement of multiple entire exons at kilobase scale, potentially addressing large genes and high ...
ascopubs.org

Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non–Small-Cell Lung Cancer and ...

Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer Patients with ...